

Docket No.: 56086-CON 71699)

(PATENT)

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of:

Signe E. Varner et al.

Application No.: 10/740,698

Confirmation No.: 3885

Filed: December 19, 2003

Art Unit: 3767

For: DEVICES FOR INTRAOCULAR DRUG

Examiner: B. Huh

**DELIVERY** 

## **INFORMATION DISCLOSURE STATEMENT (IDS)**

MS Amendment Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Dear Sir:

Pursuant to 37 CFR 1.56, 1.97 and 1.98, the attention of the Patent and Trademark Office is hereby directed to the references listed on the attached PTO/SB/08. It is respectfully requested that the information be expressly considered during the prosecution of this application, and that the references be made of record therein and appear among the "References Cited" on any patent to issue therefrom.

This Information Disclosure Statement is filed more than three months after the U.S. filing date, OR more than three months after the date of entry of the national stage of a PCT application, AND after the mailing date of the first Office Action on the merits, whichever occurs first, but before the mailing date of a Final Office Action or Notice of Allowance (37 CFR 1.97(c)).

12/14/2006 EAREGAY1 00000073 041105 10740698

04 FC:1806

180.00 DA

Application No.: 10/740,698 2 Docket No.: 56086-CON (71699)

In accordance with 37 CFR 1.98(a)(2)(ii), Applicant has not submitted copies of U.S. patents and U.S. patent applications. Applicant submits herewith copies of foreign patents and non-patent literature in accordance with 37 CFR 1.98(a)(2).

Please charge our Deposit Account No. 04-1105 in the amount of \$3,390.00 covering the fees set forth in 37 CFR 1.17(p), 1.16(i), 1.16(h), and 1.16(j). The Director is hereby authorized to charge any deficiency in the fees filed, asserted to be filed or which should have been filed herewith (or with any paper hereafter filed in this application by this firm) to our Deposit Account No. 04-1105, under Order No. 56086CON(71699). A duplicate copy of this paper is enclosed.

Dated: December 11, 2006

Respectfully/submitted

Lisa Swiszcz Hazzard

Registration No.: 44,368

EDWARDS ANGELL RALMER & DODGE

LLP

P.O. Box 55874

Boston, Massachusetts 02205

(617) 439-4444

Attorneys/Agents For Applicant

PTO/SB/08A/B (09-06)

Approved for use through 03/31/2007. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

DEC 1 1 2006 Substitute for form 1449/PTO YNFORMATION DISCLOSURE STATEMENT BY APPLICANT

Complete if Known Application Number 10/740,698-Conf. #3885 Filing Date December 19, 2003 First Named Inventor Signe E. Varner Art Unit 3767 Examiner Name

(Use as many sheets as necessary)

B. Huh Sheet of 3 1 Attorney Docket Number 56086CON(71699)

	U.S. PATENT DOCUMENTS						
Examiner Initials*	Cite No.1	Document Number  Number-Kind Code <sup>2</sup> ( if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear		
	AA*	US-273,410	03-06-1883	Wadleigh	, ignor ppec		
	AB*	US-3,416,530		Ness			
	AC*	US-4,069,307		Higuchi et al.			
	AD*	US-4,144,317		Higuchi et al.			
	AE*	US-4,304,765	12-08-1981	Shell et al.			
	AF*	US-4,764,377	08-16-1988	Goodson			
	AG*	US-4,892,736	01-09-1990	Goodson			
	AH*	US-5,246,867	09-21-1993	Lakowicz et al.	-		
	AI*	US-5,501,856		Ohtori et al.			
	AJ*	US-5,578,075	11-26-1996	Dayton			
	AK*	US-5,679,400	10-21-1997	Tuch			
	AL*	US-5,725,493	03-10-1998	Avery, et al.			
	AM*	US-5,766,242	06-16-1998	Wong et al.			
	AN*	US-5,773,019		Ashton et al.			
	AO*	US-5,830,173	11-03-1998				
	AP*	US-5,989,579		Darougar et al.			
	AQ*	US-6,153,252		Hossainy et al.	-		
		US-6,177,095	01-23-2001	Sawhney et al.			
	AS*	US-6,187,370	02-13-2001	Dinh et al.			
	AT*	US-6,214,901	04-10-2001	Chudzik et al.			
	AU*	US-6,217,895	04-17-2001	Guo et al.			
	AV*	US-6,331,313		Wong et al.			
		US-6344,035	02-05-2002	Chudzik et al.			
		US-6,375,972	04-23-2002				
		US-6,399,144		Dinh et al.			
		US-6,399,655	06-04-2002				
		US-6,548,078	04-15-2003				
		US-6,713,081		Robinson et al.			
		US-6,719,750	02-28-2002				
		US-2002/0032434		Chudzik et al.			
		US-2002/0114823		Sirhan et al.			
		US-2002/0165265	11-07-2002				
		US-2002/0168394		Hossainy et al.			
		US-2002/0188037		Chudzik et al.			
		US-2002/0198511		Varner et al.			
		US-2003/0014036		Varner et al.			
		US-2003/0021828		Guo et al.			
		US-2003/0031780		Chudzik et al.			
		US-2003/0158598		Ashton et al.			
		US-2004/0022853		Ashton et al.			
_		US-2004/0047911		Lyu et al.			
		US-2004/0121014		Guo et al.			

Examiner	Date
Signature	Considered
579673	

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Sut	ostitute for form 1449/PTO			Complete if Known		
				Application Number	10/740,698-Conf. #3885	
11	NFORMATION	1 DI	SCLOSURE	Filing Date	December 19, 2003	
l S	TATEMENT E	3Y /	APPLICANT	First Named Inventor	Signe E. Varner	
				Art Unit	3767	
	(Use as many sh	eets as	s necessary)	Examiner Name	B. Huh	
Sheet	2	of	3	Attorney Docket Number	56086CON(71699)	

	FOREIGN PATENT DOCUMENTS							
Examiner Initials*	Cite No.1	Foreign Patent Document  Country Code <sup>3</sup> -Number <sup>4</sup> -Kind Code <sup>5</sup> ( <i>ff known</i> )	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear			
	ВА	WO-89/05664	06-29-1989	ALLIED-SIGNAL INC.				
	ВВ	WO-95/03036	02-02-1995	ANGIOGENESIS TECHNOLOGIES, INC				
	ВС	WO-97/10011	03-20-1997	SCHNEIDER (USA) INC.				
	BD	WO-97/37640	10-16-1997	ALZA CORPORATION				
	BE	WO-98/32474	07-30-1998	STS BIOPOLYMERS, INC.				
	BF	WO-98/58690		STS BIOPOLYMERS, INC.				
	BG	WO-99/01114		EURO-CELTIQUE, S.A.				
	вн	WO-99/36071	07-22-1999	KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY				
	ВІ	WO-99/55396	11-04-1999	SURMODICS, INC.				
	BJ	WO-00/02564	01-20-2000	THE UNIVERSITY OF SYDNEY				
	ВК	WO-00/21584	04-20-2000	BOSTON SCIENTIFIC LIMITED				
	BL	WO-01/08718	02-08-2001	EDWARDS LIFESCIENCES CORPORATION				
	ВМ	WO-01/30323	05-03-2001	OCULEX PHARMACEUTICALS, INC.				
	BN	WO-01/32140	05-10-2001	DAROUGAR, Sohrab				
	ВО	WO-02/056790	07-25-2002	AVANTEC VASCULAR CORPORATION				
	BP	WO-02/17831	03-07-2002	JOHN HOPKINS UNIVERSITY				
	BQ	WO-03/026718	04-03-2003	COOK INCORPORATED				
	BR	WO-04/028477	04-08-2004	SURMODICS, INC.				
	BS	EP-0623354	04-20-1994					
	вт	EA-0734721	03-20-1996					
	BU	EA-0832655	06-10-1997					
	BV	EP-0879595	04-21-1998					
	BW	EP-0923953	06-19-1998					

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. \*CITE NO.: Those application(s) which are marked with an single asterisk (\*) next to the Cite No. are not supplied (under 37 CFR 1.98(a)(2)(iii)) because that application was filed after June 30, 2003 or is available in the IFW. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at <a href="https://www.uspto.gov">www.uspto.gov</a> or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Examiner	Date	
Signature	Considered	ŀ
	<del>- 1,</del>	

PTO/SB/08A/B (09-06)
Approved for use through 03/31/2007. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO				Complete if Known		
				Application Number	10/740,698-Conf. #3885	
11	NFORMATION	1 DI	SCLOSURE	Filing Date	December 19, 2003	
S	TATEMENT E	3Y /	APPLICANT	First Named Inventor	Signe E. Varner	
				Art Unit	3767	
	(Use as many she	eets as	; necessary)	Examiner Name	B. Huh	
Sheet	3	of	3	Attorney Docket Number	56086CON(71699)	

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T²
	CA	Berger et al., "Intravitreal Sustained Release Corticosteroid-5-Fluoruracil Conjugate in the Treatment of Experimental Proliferative Vitreoretinopathy," <u>Investigative Opthalmology &amp; Visual Science</u> , Vol. 37, No. 2, pp. 2318-2325 (October. 1996).	
	СВ	Berger et al., "Intravitreal Sustained Release Dexamethasone/5-FU Device in the Treatment of Experimental PVR," <u>Investigative Opthalmology &amp; Visual Science</u> , Vol. 35, No. 4, p. 1923 (March 15, 1994).	
	CC	Ishibashi et al, "Effects of Intravitreal Administration of Seroids on Experimental subretinal Neovascularization in the Subhuman Primate," <u>Arch Ophihalmol</u> , Vol. 103, pp. 708-711 (may 1985).	
	CD	Jaffee et al., "Intravitreal Sustained Release Triamcinolone/5-FU Conjugate Suspension in the Treatment of Experimental," <u>Investigative Ophthalmology &amp; Visual Science</u> , Vol. 36, No. 4, p. S161 (March 15, 1995).	
	CE	Zhou et al., "A Multi-Drug Controlled-Release Implant for Intraocular Treatment of Proliferative Vitreoretinopathy," Proc. Int. Symp. Control. re. Bioact. Mater., Vol. 24, pp. 625-626 (1997).	
	CF	Zhou et al., "Development of a multiple-drug delivery implant for intraocular management of proliferative vitreoretinopathy," Journal of Controlled Release, Vol. 55, pp. 281-295 (1998).	-
	CG	Jaffee et al., "Safety and Pharmacokinetics of an Intraocular Fluocinolone Acetonide Sustained Delivery Device," <u>Investigative Ophthalmology &amp; Visual Science</u> , Vol. 41, No. 11 pp. 3569-3575 (October 2000).	
	СН	Varner et al., "Development of a Minimally Invasive Intravitreal Implant for Drug Delivery," ARVO Abstracts Online, 4 pages (May 8, 2003).	

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Examiner	Date	
Signature	 Considered	
570070		

<sup>&</sup>lt;sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>Applicant is to place a check mark here if English language Translation is attached.